Literature DB >> 18801559

Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy, and distal pancreatectomy.

Siobhan M Kehoe1, Eric L Eisenhauer, Dennis S Chi.   

Abstract

Patients with advanced-stage ovarian cancer often have metastatic disease in the upper abdominal region. In particular, metastases to the diaphragm are exceedingly common in these patients. A comprehensive approach to surgical cytoreduction, which has been associated with improved survival in patients with advanced ovarian cancer, should incorporate upper abdominal resection.

Entities:  

Mesh：

Year:  2008        PMID： 18801559     DOI： 10.1016/j.ygyno.2008.07.053

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


  14 in total

1.  Maximal cytoreductive effort in epithelial ovarian cancer surgery.

Authors:  Karin K Shih; Dennis S Chi
Journal:  J Gynecol Oncol       Date:  2010-06-30       Impact factor: 4.401

2.  The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum.

Authors:  Oliver Zivanovic; Camelia S Sima; Alexia Iasonos; William J Hoskins; Pavani R Pingle; Mario M M Leitao; Yukio Sonoda; Nadeem R Abu-Rustum; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2010-03       Impact factor: 5.482

3.  Extraperitoneal Approach During Peritonectomy in the Right Upper Quadrant for Peritoneal Metastases from Ovarian Malignancies.

Authors:  Miklos Acs; Hubert Leebmann; Sebastian Häusler; Philipp Harter; Pompiliu Piso
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

4.  Application of J-Plasma in the excision of diaphragmatic lesions as part of complete cytoreduction in patients with advanced ovarian cancer.

Authors:  Vasilios Theodoulidis; Anastasia Prodromidou; Emmanouil Stamatakis; Nicholas Alexakis; Alexandros Rodolakis; Dimitrios Haidopoulos
Journal:  Mol Clin Oncol       Date:  2022-05-18

5.  Risk factors of perioperative complications and management with enhanced recovery after primary surgery in women with epithelial ovarian carcinoma in a single center.

Authors:  Min Li; Tianjiao Zhang; Jing Zhu; Yuebo Li; Wenying Chen; Yanhu Xie; Wei Zhang; Rongzhu Chen; Wei Wei; Guihong Wang; Jiwei Qin; Weidong Zhao; Dabao Wu; Zhen Shen; Björn Nashan; Ying Zhou
Journal:  Oncol Lett       Date:  2022-03-16       Impact factor: 3.111

6.  Incidental events of diaphragmatic surgery in 82 patients with advanced ovarian, primary peritoneal and fallopian tubal cancer.

Authors:  Fumitoshi Terauchi; Aikou Okamoto; Yumiko Wada; Ei Hasegawa; Toru Sasaki; Osamu Akutagawa; Yasukazu Sagawa; Hirotaka Nishi; Keiichi Isaka
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

7.  Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.

Authors:  Renee A Cowan; Jill Tseng; Vijayashree Murthy; Radhika Srivastava; Kara C Long Roche; Oliver Zivanovic; Ginger J Gardner; Dennis S Chi; Bernard J Park; Yukio Sonoda
Journal:  Gynecol Oncol       Date:  2017-09-06       Impact factor: 5.482

8.  Complications and Outcomes of Diaphragm Surgeries in Epithelial Ovarian Malignancies.

Authors:  Amrita Datta; Ajit Sebastian; Rachel George Chandy; Vinotha Thomas; Dhanya Susan Thomas; Reka Karuppusami; Anitha Thomas; Abraham Peedicayil
Journal:  Indian J Surg Oncol       Date:  2021-09-08

9.  Diaphragmatic peritonectomy versus full thickness diaphragmatic resection and pleurectomy during cytoreduction in patients with ovarian cancer.

Authors:  P N J Pathiraja; R Garruto-Campanile; R Tozzi
Journal:  Int J Surg Oncol       Date:  2013-12-18

10.  Diaphragmatic Surgery and Related Complications In Primary Cytoreduction for Advanced Ovarian, Tubal, and Peritoneal Carcinoma.

Authors:  Shuang Ye; Tiancong He; Shanhui Liang; Xiaojun Chen; Xiaohua Wu; Huijuan Yang; Libing Xiang
Journal:  BMC Cancer       Date:  2017-05-05       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.